More about sirukumab
Sirukumab, which will be called Plivensia if approved, is a human monoclonal blood protein that is produced in response to a specific antigen. The antibody specifically blocks interleukin 6 (IL-6), which is a specific cytokine in the body. IL-6 has been known to significantly contribute to the RA symptom of inflammation.
Sirukumab is intended to be an alternative drug therapy for RA patients who have been unable to find a drug that treats their disease or unable to find a drug that they can tolerate. The creators of sirukumab believe that it could be a great benefit to patients who cannot tolerate other disease modifying drugs, such as methotrexate.